Loading news...
Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization.
Elon Musk tweeted about wanting Jurassic Park in real life. Companies aren't bringing back dinosaurs yet, but they are bringing extinct items back to life.
Ginkgo Bioworks reported Q4 revenues of $33 million, down 24% year-over-year, and missing estimates by over $4 million. Cell Engineering, expected to drive growth, delivered just $125 million in 2025 revenue, far below the original $1.1 billion SPAC projection. Management is pivoting by selling the Biosecurity segment, retaining only a minority stake in the new private entity.
BOSTON, March 2, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced the official launch of Ginkgo Cloud Lab. This new interface allows researchers to transition their benchwork to Ginkgo's autonomous lab infrastructure directly through a web browser.
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2025 Earnings Call Transcript
Ginkgo Bioworks (NYSE: DNA) shares are down following the company's fourth-quarter and full-year 2025 financial report.
Ginkgo provides an update on its fourth quarter financial results BOSTON, Feb. 26, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the fourth quarter and full year ended December 31, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.
Presentation and Q&A session scheduled for post-market on Thursday, February 26, 2026 BOSTON, Feb. 19, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.
Collaboration aims to develop a commercialization-ready microorganism to manufacture next-generation peptide crop solutions at grower-friendly costs BOSTON, Feb. 18, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA, "Ginkgo") and Invaio Sciences, an agricultural biotechnology company leading in nature-positive crop protection solutions, today announced a collaboration to develop strains that can efficiently manufacture peptide-based crop protection inputs. Growers are seeking inputs that protect agricultural crops from pests that are increasingly resistant to conventional chemistry.
The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $9, representing a -3.12% change from its previous close.
Amazon delivered robust Q4 2025 results, with accelerating revenue growth and AWS leading at 23.6% YoY. AMZN's operating margin reached a historic high of 11.8%, driven by strong AWS profitability at a 35% margin. The stock sold off after management guided FY 2026 CapEx to $200bn, 50% above FY 2025 and exceeding operating cash flow by $60bn.
Ginkgo Bioworks Holdings, Inc. (DNA) reached $9.23 at the closing of the latest trading day, reflecting a -9.06% change compared to its last close.
Allegiant Travel Company demonstrates disciplined capacity management and cost control, supporting a "Buy" rating and strong post-earnings stock performance. Q4 2025 results show a swing to profitability with a 10.2% operating margin, despite modest margin compression and reduced unit revenues. ALGT targets stable capacity and efficiency gains in 2026, leveraging Boeing 737 MAX upgrades to drive cost improvements without diluting unit revenues.
Research conducted in collaboration with OpenAI using Ginkgo's cloud laboratory Preprint describes how GPT-5-driven autonomous lab significantly reduced reaction costs in cell-free protein synthesis GPT-5-driven autonomous lab executed over 36,000 experiments Ginkgo now selling the AI-improved reaction mix in its reagents store, showing commercial potential of AI-driven science BOSTON, Feb. 5, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced it has demonstrated, in collaboration with OpenAI, an AI system that autonomously designed, executed, and learned from biological experiments with minimal human involvement. In a new preprint, the company reports the system reduced cell-free protein synthesis reaction costs by 40% relative to state of the art, while running 36,000 experimental conditions across six iterative cycles.
In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $8.27, denoting a -5.92% move from the preceding trading day.
Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $9.31, signifying a -1.27% move from its prior day's close.
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $10.02, marking a -6.36% move from the previous day.
In the most recent trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $9.85, indicating a +2.39% shift from the previous trading day.
NEW YORK, Jan. 13, 2026 /PRNewswire/ -- MySize, Inc. (NASDAQ: MYSZ), a leading Israeli-based AI-driven fashion technology company, today announced that it is evaluating new opportunities to responsibly monetize its growing portfolio of aggregated and anonymized data intelligence assets. Over time, MySize's platforms have generated large-scale, privacy-compliant insights related to apparel fit trends, sizing mismatches, and product-level performance across brands and retailers.
BOSTON, Jan. 13, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) announced today that Co-Founder and CEO Jason Kelly is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 10:30 a.m.